



For Immediate Release • January 22, 2025

**Proesis Bio Earns FDA Approval for
Plasma Collection Facility in Meridian, ID**

FDA Approval Adds New Center to Proesis Bio's Growing Portfolio

Boise, ID – Wednesday, January 22, 2025 -- Proesis Bio, a leading innovator in the plasma industry, announced that its fourth plasma collection facility received approval from the U.S. Food and Drug Administration (FDA). The Meridian, Idaho, based facility commenced operations in April 2024 and with this FDA approval, is now licensed to provide human source plasma for further manufacturing in the United States.

"This FDA approval is a testament to our commitment to expanding the source plasma market," said Kris Jonas, CEO of Proesis Bio. "We extend our gratitude to the FDA for their thorough review of this facility and look forward to bringing additional facilities online to meet growing demand for plasma derived therapies."

Proesis Bio's newest facility greets plasma donors with elevated aesthetics and advanced features that provide a smooth and comfortable donation process. The company also enhances the donor experience via their innovative ProesisPlus™ app, appointment scheduling, and loyalty rewards. At full capacity, the center expects to employ 30 healthcare professionals.

"This approval would not have been possible without our team's hard work and steadfast commitment to our mission," added Jonas. "This most recent FDA approval acknowledges their efforts and reinforces our commitment to excellence." The Meridian center and its staff are an important component in positioning Proesis Bio to better serve donors and the patients who rely on high-quality plasma for life-saving therapies."

To learn more about the Proesis Bio donation process and to schedule an appointment, please visit: www.proesisbio.com or visit in person at 3015 E Goldstone Dr STE 120, Meridian, ID 83642.

Making a Difference in the Industry

Proesis Bio was established in 2022 and is comprised of a group of highly experienced individuals from the plasma industry. Their primary objective is to foster opportunities that boost the availability of source plasma, a crucial component in producing plasma-derived therapies used to treat rare and chronic diseases. For more information and a list of centers, please visit proesisbio.com.

Proesis Bio and ProesisPlus are registered trademarks of Proesis Bio in the United States. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

For Press Inquiries:

Gabby Weeks

gabby.weeks@proesisbio.com

For More Information on ProesisPlus™, Visit: ProesisBio.com.